{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+C",
    "query": {
      "intervention": "Formulation C"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 318,
    "total_pages": 32,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+C&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T02:13:04.562Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00449774",
      "title": "Bioequivalence And Effect Of Food And Water On Lamotrigine in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Mental Disorders"
      ],
      "interventions": [
        {
          "name": "Lamotrigine IR tablets",
          "type": "DRUG"
        },
        {
          "name": "Lamotrigine ODT tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "19 Years to 55 Years"
      },
      "enrollment_count": 220,
      "start_date": "2007-05-07",
      "completion_date": "2007-06-19",
      "has_results": false,
      "last_update_posted_date": "2017-08-08",
      "last_synced_at": "2026-09-03T02:13:04.562Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00449774"
    },
    {
      "nct_id": "NCT05278013",
      "title": "Utility of 2- Octyl Cyanoacrylate (2-OCA)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ascites",
        "Fluid Loss"
      ],
      "interventions": [
        {
          "name": "Dermabond",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Methodist Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 134,
      "start_date": "2022-01-13",
      "completion_date": "2024-01-13",
      "has_results": false,
      "last_update_posted_date": "2023-07-10",
      "last_synced_at": "2026-09-03T02:13:04.562Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05278013"
    },
    {
      "nct_id": "NCT02083640",
      "title": "Relative Bioavailability For Palbociclib Formulations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Palbociclib Formulation Reference",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib Formulation Test",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 30,
      "start_date": "2014-03",
      "completion_date": "2014-05",
      "has_results": false,
      "last_update_posted_date": "2014-06-04",
      "last_synced_at": "2026-09-03T02:13:04.562Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02083640"
    },
    {
      "nct_id": "NCT01272180",
      "title": "Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Invasive Meningococcal Disease"
      ],
      "interventions": [
        {
          "name": "Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV.",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Vaccines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "10 Years to 25 Years"
      },
      "enrollment_count": 484,
      "start_date": "2011-08",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2020-06-16",
      "last_synced_at": "2026-09-03T02:13:04.562Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Madera, California • Paramount, California + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Madera",
          "state": "California"
        },
        {
          "city": "Paramount",
          "state": "California"
        },
        {
          "city": "Bardstown",
          "state": "Kentucky"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01272180"
    },
    {
      "nct_id": "NCT05283681",
      "title": "A Study to Evaluate the Bioavailability of Risankizumab in Pre-filled Syringe or Auto-injector in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Risankizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 226,
      "start_date": "2019-04-02",
      "completion_date": "2019-11-11",
      "has_results": false,
      "last_update_posted_date": "2022-03-17",
      "last_synced_at": "2026-09-03T02:13:04.562Z",
      "location_count": 2,
      "location_summary": "Grayslake, Illinois • Austin, Texas",
      "locations": [
        {
          "city": "Grayslake",
          "state": "Illinois"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05283681"
    },
    {
      "nct_id": "NCT06742086",
      "title": "A Study to Evaluate the Bioavailability and Food Effects of Oral Venetoclax New Tablet Formulation 2.0 in Healthy Adult Female Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 72,
      "start_date": "2024-12-19",
      "completion_date": "2025-10-08",
      "has_results": false,
      "last_update_posted_date": "2025-10-15",
      "last_synced_at": "2026-09-03T02:13:04.562Z",
      "location_count": 2,
      "location_summary": "Grayslake, Illinois • Austin, Texas",
      "locations": [
        {
          "city": "Grayslake",
          "state": "Illinois"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06742086"
    },
    {
      "nct_id": "NCT06733675",
      "title": "Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer",
        "Pharmacokinetics",
        "Safety",
        "Drug-Drug Interaction (DDI)",
        "FDC"
      ],
      "interventions": [
        {
          "name": "Ledaborbactam etzadroxil",
          "type": "DRUG"
        },
        {
          "name": "Ceftibuten",
          "type": "DRUG"
        },
        {
          "name": "Ceftibuten-ledaborbactam etzadroxil",
          "type": "DRUG"
        },
        {
          "name": "Esomeprazole",
          "type": "DRUG"
        },
        {
          "name": "amoxicillin-clavulanate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Basilea Pharmaceutica",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 96,
      "start_date": "2025-01-07",
      "completion_date": "2026-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-09-03T02:13:04.562Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06733675"
    },
    {
      "nct_id": "NCT05767905",
      "title": "A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "PF-06821497 Treatment A",
          "type": "DRUG"
        },
        {
          "name": "PF-06821497 Treatment B",
          "type": "DRUG"
        },
        {
          "name": "PF-06821497 Treatment C",
          "type": "DRUG"
        },
        {
          "name": "PF-06821497 Treatment D",
          "type": "DRUG"
        },
        {
          "name": "PF-06821497 Treatment E",
          "type": "DRUG"
        },
        {
          "name": "PF-06821497 Treatment F",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2023-03-17",
      "completion_date": "2023-06-20",
      "has_results": true,
      "last_update_posted_date": "2025-06-12",
      "last_synced_at": "2026-09-03T02:13:04.562Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05767905"
    },
    {
      "nct_id": "NCT06619314",
      "title": "A Study to Evaluate the Effect of Food, Formulation, and a Proton Pump Inhibitor (PPI) on Calderasib (MK-1084) in Healthy Adult Participants (MK-1084-003)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Calderasib",
          "type": "DRUG"
        },
        {
          "name": "PPI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "19 Years to 55 Years"
      },
      "enrollment_count": 56,
      "start_date": "2023-09-20",
      "completion_date": "2023-11-25",
      "has_results": false,
      "last_update_posted_date": "2026-02-11",
      "last_synced_at": "2026-09-03T02:13:04.562Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06619314"
    },
    {
      "nct_id": "NCT00088452",
      "title": "Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Childhood Absence Epilepsy",
        "Petit Mal Epilepsy",
        "Epilepsy",
        "Seizures"
      ],
      "interventions": [
        {
          "name": "Ethosuximide",
          "type": "DRUG"
        },
        {
          "name": "Lamotrigine",
          "type": "DRUG"
        },
        {
          "name": "Valproic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Months",
        "maximum_age": "13 Years",
        "sex": "ALL",
        "summary": "30 Months to 13 Years"
      },
      "enrollment_count": 453,
      "start_date": "2004-07",
      "completion_date": "2016-08-31",
      "has_results": true,
      "last_update_posted_date": "2020-10-14",
      "last_synced_at": "2026-09-03T02:13:04.562Z",
      "location_count": 31,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00088452"
    }
  ]
}